👪

Inheritance

1

Autosomal Dominant HP:0000006

Autosomal dominant inheritance

Show evidence (1 reference)

PMID:8261652 SUPPORT Human Clinical

"We report five members of a family with dacryocystitis associated with osteopoikilosis. The inheritance is autosomal dominant."

The original family report demonstrates autosomal dominant inheritance across multiple generations.

⚙

Pathophysiology

3

LEMD3/MAN1 Loss-of-Function and Dysregulated TGF-beta/BMP Signaling

Osteopoikilosis is caused by heterozygous loss-of-function mutations in LEMD3 (also called MAN1), which encodes an inner nuclear membrane protein. The C-terminal domain of LEMD3 binds receptor-activated SMADs and antagonizes both BMP and TGF-beta/activin signaling pathways. Loss of this antagonism leads to excessive SMAD-mediated signaling, perturbing bone formation and remodeling and producing focal osteosclerotic lesions.

osteoblast link fibroblast link

LEMD3 link

negative regulation of BMP signaling pathway link negative regulation of TGF-beta receptor signaling pathway link endochondral ossification link

Downstream

Focal Osteosclerosis (Osteopoikilosis) Disinhibition of BMP/TGF-beta-SMAD signaling in osteoblast lineage cells leads to dysregulated bone maturation and formation of focal osteosclerotic bone islands.

Lacrimal Canal Stenosis Excessive TGF-beta signaling in fibroblasts may drive fibroproliferative and stenosing connective tissue changes in the nasolacrimal drainage system.

Dupuytren Contracture Disinhibited TGF-beta signaling in fibroblasts drives palmar fibromatosis as part of the generalized fibroproliferative phenotype.

Keloids Excessive TGF-beta-SMAD signaling promotes fibroblast proliferation and abnormal scar collagen deposition.

Digital Flexor Tenosynovitis Stenosing tenosynovitis (trigger finger) results from fibroproliferative thickening of tendon sheaths driven by dysregulated TGF-beta signaling.

Show evidence (3 references)

PMID:15489854 PARTIAL Human Clinical

"All the affected individuals that we investigated were heterozygous with respect to a loss-of-function mutation in LEMD3 (also called MAN1), which encodes an inner nuclear membrane protein."

Landmark genetic study confirming LEMD3 loss-of-function mutations in osteopoikilosis/Buschke-Ollendorff syndrome families; mechanism inferred to apply to the dacryocystitis-osteopoikilosis pedigree, which was not directly molecularly tested.

PMID:15489854 SUPPORT Human Clinical

"LEMD3 interacted with BMP and activin-TGFbeta receptor-activated Smads and antagonized both signaling pathways in human cells."

Demonstrates the molecular mechanism by which LEMD3 antagonizes BMP and TGF-beta signaling; applies directly to the pathogenic mechanism regardless of which specific pedigree is studied.

PMID:17087626 PARTIAL Human Clinical

"In 2004, others discovered that heterozygous, loss-of-function, germline mutations in the LEMD3 gene (LEMD3 or MAN1) cause both osteopoikilosis (OPK) and Buschke-Ollendorff syndrome (BOS)."

Confirms LEMD3 loss-of-function mutations in additional OPK/BOS families; these pedigrees do not include patients with the combined dacryocystitis-osteopoikilosis phenotype, so this is an inference from adjacent disorders.

Focal Osteosclerosis (Osteopoikilosis)

Multiple small, discrete, symmetric periarticular osteosclerotic bone lesions (2-10mm diameter) distributed in the epiphyses and metaphyses of long bones, carpal and tarsal bones, and pelvis. These lesions represent areas of focal defective endochondral bone maturation with osteosclerotic trabeculae.

osteoblast link

endochondral ossification link BMP signaling pathway link

bone element link

Downstream

Increased Bone Mineral Density The osteosclerotic bone islands of osteopoikilosis represent focal areas of increased bone mineral density.

Arthralgia Joint pain occurs in 15-20% of patients with osteopoikilosis, potentially related to periarticular osteosclerotic lesions.

Joint Swelling Joint effusion occasionally accompanies osteopoikilosis lesions.

Show evidence (2 references)

PMID:17087626 SUPPORT Human Clinical

"OPK is an autosomal dominant, usually benign, skeletal dysplasia featuring multiple, small, especially metaphyseal, oval or round, dense trabecular foci distributed symmetrically throughout the skeleton."

Describes the characteristic radiographic features of osteopoikilosis lesions.

PMID:25352085 SUPPORT Human Clinical

"Osteopoikilosis (OPK) is a benign, rare, asymptomatic osteosclerotic bone dysplasia which is inherited as an autosomal dominant trait."

Confirms OPK as a benign autosomal dominant osteosclerotic dysplasia.

Lacrimal Canal Stenosis

Stenosis of the lacrimal sac or nasolacrimal canal leads to impaired tear drainage and chronic dacryocystitis. The stenosis is hypothesized to arise from fibroproliferative connective tissue changes related to the underlying LEMD3-associated connective tissue disorder, analogous to stenosing lesions seen at other sites in the osteopoikilosis spectrum.

fibroblast link

lacrimal sac link nasolacrimal duct link

Show evidence (1 reference)

PMID:8261652 SUPPORT Human Clinical

"We report five members of a family with dacryocystitis associated with osteopoikilosis. The inheritance is autosomal dominant."

The original syndromic report establishing co-occurrence of dacryocystitis with osteopoikilosis in a single family with autosomal dominant inheritance.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

10

Eye 1

Epiphora FREQUENT Epiphora (HP:0009926)

Show evidence (1 reference)

PMID:34986808 PARTIAL Human Clinical

"Epiphora with continuous purulent discharge was the most common clinical sign reported by 144 (52.4%) patients"

Large clinical series confirms epiphora as the most common presenting symptom in acquired nasolacrimal duct obstruction with dacryocystitis.

Head and Neck 2

Dacryocystitis OBLIGATE Dacryocystitis (HP:0000620)

Sequelae: Epiphora

Show evidence (1 reference)

PMID:8261652 SUPPORT Human Clinical

"We report five members of a family with dacryocystitis associated with osteopoikilosis. The inheritance is autosomal dominant."

All five affected members in the original pedigree had dacryocystitis.

Lacrimal Duct Stenosis FREQUENT Lacrimal duct stenosis (HP:0007678)

Sequelae: Dacryocystitis Epiphora

Show evidence (1 reference)

PMID:8261652 SUPPORT Human Clinical

"We report five members of a family with dacryocystitis associated with osteopoikilosis. The inheritance is autosomal dominant."

Dacryocystitis in the original family implies lacrimal duct stenosis as the underlying anatomical defect.

Integument 1

Keloids OCCASIONAL Keloids (HP:0010562)

Show evidence (1 reference)

PMID:14521305 SUPPORT Human Clinical

"We report a family in whom various members had osteopoikilosis with 5 different associated lesions. We suggest that osteopoikilosis is a bone manifestation of a generalized fibroproliferative or stenosing disease."

Keloid formation is among the fibroproliferative lesions reported in the Gunal family with osteopoikilosis.

Limbs 1

Dupuytren Contracture OCCASIONAL Dupuytren contracture (HP:0005679)

Show evidence (1 reference)

PMID:14521305 SUPPORT Human Clinical

"We report a family in whom various members had osteopoikilosis with 5 different associated lesions. We suggest that osteopoikilosis is a bone manifestation of a generalized fibroproliferative or stenosing disease."

Dupuytren contracture is among the fibroproliferative lesions reported in the Gunal family with osteopoikilosis.

Metabolism 1

Joint Swelling OCCASIONAL Joint swelling (HP:0001386)

Show evidence (1 reference)

PMID:25352085 SUPPORT Human Clinical

"Although it is usually asymptomatic, effusion and joint pain can be found in 15-20 % of patients."

Documents that joint effusion/swelling occurs in a minority of osteopoikilosis patients.

Musculoskeletal 3

Osteopoikilosis OBLIGATE Osteopoikilosis (HP:0010739)

Sequelae: Arthralgia Joint Swelling

Show evidence (2 references)

PMID:8261652 SUPPORT Human Clinical

"We report five members of a family with dacryocystitis associated with osteopoikilosis. The inheritance is autosomal dominant."

All five affected members in the original pedigree had osteopoikilosis demonstrated radiologically.

PMID:17087626 SUPPORT Human Clinical

"OPK is an autosomal dominant, usually benign, skeletal dysplasia featuring multiple, small, especially metaphyseal, oval or round, dense trabecular foci distributed symmetrically throughout the skeleton."

Characterizes the typical radiographic appearance of osteopoikilosis.

Increased Bone Mineral Density OBLIGATE Increased bone mineral density (HP:0011001)

Show evidence (1 reference)

PMID:25352085 SUPPORT Human Clinical

"Osteopoikilosis (OPK) is a benign, rare, asymptomatic osteosclerotic bone dysplasia which is inherited as an autosomal dominant trait."

Osteosclerotic bone dysplasia directly implies increased bone mineral density at the lesion sites.

Digital Flexor Tenosynovitis VERY_RARE Digital flexor tenosynovitis (HP:0012276)

Show evidence (1 reference)

PMID:14521305 SUPPORT Human Clinical

"We report a family in whom various members had osteopoikilosis with 5 different associated lesions. We suggest that osteopoikilosis is a bone manifestation of a generalized fibroproliferative or stenosing disease."

Trigger finger (stenosing digital flexor tenosynovitis) is among the lesions reported in the Gunal osteopoikilosis family.

Constitutional 1

Arthralgia OCCASIONAL Arthralgia (HP:0002829)

Show evidence (1 reference)

PMID:25352085 SUPPORT Human Clinical

"Although it is usually asymptomatic, effusion and joint pain can be found in 15-20 % of patients."

Documents that arthralgia occurs in a minority of osteopoikilosis patients.

🧬

Genetic Associations

1

LEMD3 (Causative (inferred))

Show evidence (2 references)

PMID:15489854 PARTIAL Human Clinical

"All the affected individuals that we investigated were heterozygous with respect to a loss-of-function mutation in LEMD3 (also called MAN1), which encodes an inner nuclear membrane protein."

Identifies LEMD3 as the causative gene for osteopoikilosis in multiple families; LEMD3 is inferred (not directly tested) as the causative gene in the dacryocystitis-osteopoikilosis pedigree.

PMID:17087626 PARTIAL Human Clinical

"We confirm that OPK and BOS individuals, including those with MEL-like lesions, have heterozygous, deactivating, germline LEMD3 mutations."

Confirms deactivating LEMD3 mutations in additional OPK/BOS families; these families did not have the combined dacryocystitis phenotype, so this supports the inference but is not direct evidence for the combined syndrome.

💊

Treatments

4

Dacryocystorhinostomy

Action: dacryocystorhinostomy Ontology label: surgical procedure on nasolacrimal duct MAXO:0025005

Surgical procedure to create a new drainage pathway from the lacrimal sac directly into the nasal cavity, bypassing the obstructed nasolacrimal duct. May be necessary in cases of chronic or recurrent dacryocystitis that do not respond to conservative management.

Antibiotic Therapy

Antibiotics prescribed to manage acute bacterial infections associated with dacryocystitis episodes. Typically includes topical and systemic antibiotics.

Observation and Reassurance for Osteopoikilosis

Action: supportive care MAXO:0000950

Osteopoikilosis itself is typically benign and asymptomatic, requiring no specific treatment in most cases. Affected individuals should be reassured of the non-progressive and non-malignant nature of the bone lesions. Clinical monitoring without intervention is appropriate for asymptomatic cases.

Show evidence (1 reference)

PMID:25352085 SUPPORT Human Clinical

"Osteopoikilosis (OPK) is a benign, rare, asymptomatic osteosclerotic bone dysplasia which is inherited as an autosomal dominant trait."

Confirms osteopoikilosis is typically benign and asymptomatic, supporting a management approach of observation and reassurance rather than active intervention.

Analgesic Therapy for Arthralgia

Action: pharmacotherapy MAXO:0000058

For the minority of patients who develop joint pain (arthralgia) or joint effusion associated with periarticular osteosclerotic lesions, symptomatic management with analgesics or anti-inflammatory agents is appropriate. No disease-specific treatment is required for osteopoikilosis-associated arthralgia.

Show evidence (1 reference)

PMID:25352085 PARTIAL Human Clinical

"Although it is usually asymptomatic, effusion and joint pain can be found in 15-20 % of patients."

Documents that a minority of osteopoikilosis patients experience joint symptoms warranting symptomatic pain management; specific analgesic regimens are not detailed in this report.

{ }

Source YAML

click to show

name: Dacryocystitis-Osteopoikilosis Syndrome
creation_date: "2026-03-07T00:00:00Z"
category: Mendelian
parents:
  - Musculoskeletal Disease
  - Ophthalmological Disease
  - Genetic Disease
disease_term:
  preferred_term: dacryocystitis-osteopoikilosis syndrome
  term:
    id: MONDO:0008158
    label: dacryocystitis-osteopoikilosis syndrome
inheritance:
  - name: Autosomal Dominant
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
    evidence:
      - reference: PMID:8261652
        reference_title: "Dacryocystitis associated with osteopoikilosis."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "We report five members of a family with dacryocystitis associated with osteopoikilosis. The inheritance is autosomal dominant."
        explanation: The original family report demonstrates autosomal dominant inheritance across multiple generations.
prevalence:
  - population: Published family reports
    percentage: 5 affected members in a single reported family
    notes: >-
      No population-based prevalence estimate was identified. The original
      syndrome report described five affected members in one family and noted no
      prior published association, indicating an exceptionally rare condition.
    evidence:
      - reference: PMID:8261652
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "We report five members of a family with dacryocystitis associated with osteopoikilosis. The inheritance is autosomal dominant. Review of the literature revealed no other report of this kind of association."
        explanation: The original syndrome-defining report documents only one affected family and explicitly notes no prior literature reports.
pathophysiology:
  - name: LEMD3/MAN1 Loss-of-Function and Dysregulated TGF-beta/BMP Signaling
    description: >
      Osteopoikilosis is caused by heterozygous loss-of-function mutations in LEMD3
      (also called MAN1), which encodes an inner nuclear membrane protein. The C-terminal
      domain of LEMD3 binds receptor-activated SMADs and antagonizes both BMP and
      TGF-beta/activin signaling pathways. Loss of this antagonism leads to excessive
      SMAD-mediated signaling, perturbing bone formation and remodeling and producing
      focal osteosclerotic lesions.
    cell_types:
      - preferred_term: osteoblast
        term:
          id: CL:0000062
          label: osteoblast
      - preferred_term: fibroblast
        term:
          id: CL:0000057
          label: fibroblast
    biological_processes:
      - preferred_term: negative regulation of BMP signaling pathway
        term:
          id: GO:0030514
          label: negative regulation of BMP signaling pathway
      - preferred_term: negative regulation of TGF-beta receptor signaling pathway
        term:
          id: GO:0030512
          label: negative regulation of transforming growth factor beta receptor signaling pathway
      - preferred_term: endochondral ossification
        term:
          id: GO:0001958
          label: endochondral ossification
    genes:
      - preferred_term: LEMD3
        term:
          id: hgnc:28887
          label: LEMD3
    downstream:
      - target: Focal Osteosclerosis (Osteopoikilosis)
        description: >
          Disinhibition of BMP/TGF-beta-SMAD signaling in osteoblast lineage cells
          leads to dysregulated bone maturation and formation of focal osteosclerotic
          bone islands.
      - target: Lacrimal Canal Stenosis
        description: >
          Excessive TGF-beta signaling in fibroblasts may drive fibroproliferative
          and stenosing connective tissue changes in the nasolacrimal drainage system.
      - target: Dupuytren Contracture
        description: >
          Disinhibited TGF-beta signaling in fibroblasts drives palmar fibromatosis
          as part of the generalized fibroproliferative phenotype.
      - target: Keloids
        description: >
          Excessive TGF-beta-SMAD signaling promotes fibroblast proliferation and
          abnormal scar collagen deposition.
      - target: Digital Flexor Tenosynovitis
        description: >
          Stenosing tenosynovitis (trigger finger) results from fibroproliferative
          thickening of tendon sheaths driven by dysregulated TGF-beta signaling.
    evidence:
      - reference: PMID:15489854
        reference_title: "Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis."
        supports: PARTIAL
        evidence_source: HUMAN_CLINICAL
        snippet: "All the affected individuals that we investigated were heterozygous with respect to a loss-of-function mutation in LEMD3 (also called MAN1), which encodes an inner nuclear membrane protein."
        explanation: Landmark genetic study confirming LEMD3 loss-of-function mutations in osteopoikilosis/Buschke-Ollendorff syndrome families; mechanism inferred to apply to the dacryocystitis-osteopoikilosis pedigree, which was not directly molecularly tested.
      - reference: PMID:15489854
        reference_title: "Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "LEMD3 interacted with BMP and activin-TGFbeta receptor-activated Smads and antagonized both signaling pathways in human cells."
        explanation: Demonstrates the molecular mechanism by which LEMD3 antagonizes BMP and TGF-beta signaling; applies directly to the pathogenic mechanism regardless of which specific pedigree is studied.
      - reference: PMID:17087626
        reference_title: "Deactivating germline mutations in LEMD3 cause osteopoikilosis and Buschke-Ollendorff syndrome, but not sporadic melorheostosis."
        supports: PARTIAL
        evidence_source: HUMAN_CLINICAL
        snippet: "In 2004, others discovered that heterozygous, loss-of-function, germline mutations in the LEMD3 gene (LEMD3 or MAN1) cause both osteopoikilosis (OPK) and Buschke-Ollendorff syndrome (BOS)."
        explanation: Confirms LEMD3 loss-of-function mutations in additional OPK/BOS families; these pedigrees do not include patients with the combined dacryocystitis-osteopoikilosis phenotype, so this is an inference from adjacent disorders.
  - name: Focal Osteosclerosis (Osteopoikilosis)
    description: >
      Multiple small, discrete, symmetric periarticular osteosclerotic bone lesions
      (2-10mm diameter) distributed in the epiphyses and metaphyses of long bones,
      carpal and tarsal bones, and pelvis. These lesions represent areas of focal
      defective endochondral bone maturation with osteosclerotic trabeculae.
    locations:
      - preferred_term: bone element
        term:
          id: UBERON:0001474
          label: bone element
    cell_types:
      - preferred_term: osteoblast
        term:
          id: CL:0000062
          label: osteoblast
    biological_processes:
      - preferred_term: endochondral ossification
        term:
          id: GO:0001958
          label: endochondral ossification
      - preferred_term: BMP signaling pathway
        term:
          id: GO:0030509
          label: BMP signaling pathway
    downstream:
      - target: Increased Bone Mineral Density
        description: >
          The osteosclerotic bone islands of osteopoikilosis represent focal areas
          of increased bone mineral density.
      - target: Arthralgia
        description: >
          Joint pain occurs in 15-20% of patients with osteopoikilosis,
          potentially related to periarticular osteosclerotic lesions.
      - target: Joint Swelling
        description: >
          Joint effusion occasionally accompanies osteopoikilosis lesions.
    evidence:
      - reference: PMID:17087626
        reference_title: "Deactivating germline mutations in LEMD3 cause osteopoikilosis and Buschke-Ollendorff syndrome, but not sporadic melorheostosis."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "OPK is an autosomal dominant, usually benign, skeletal dysplasia featuring multiple, small, especially metaphyseal, oval or round, dense trabecular foci distributed symmetrically throughout the skeleton."
        explanation: Describes the characteristic radiographic features of osteopoikilosis lesions.
      - reference: PMID:25352085
        reference_title: "Osteopoikilosis: report of a familial case and review of the literature."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Osteopoikilosis (OPK) is a benign, rare, asymptomatic osteosclerotic bone dysplasia which is inherited as an autosomal dominant trait."
        explanation: Confirms OPK as a benign autosomal dominant osteosclerotic dysplasia.
  - name: Lacrimal Canal Stenosis
    description: >
      Stenosis of the lacrimal sac or nasolacrimal canal leads to impaired tear drainage
      and chronic dacryocystitis. The stenosis is hypothesized to arise from
      fibroproliferative connective tissue changes related to the underlying LEMD3-associated
      connective tissue disorder, analogous to stenosing lesions seen at other sites in
      the osteopoikilosis spectrum.
    locations:
      - preferred_term: lacrimal sac
        term:
          id: UBERON:0001351
          label: lacrimal sac
      - preferred_term: nasolacrimal duct
        term:
          id: UBERON:0002392
          label: nasolacrimal duct
    cell_types:
      - preferred_term: fibroblast
        term:
          id: CL:0000057
          label: fibroblast
    evidence:
      - reference: PMID:8261652
        reference_title: "Dacryocystitis associated with osteopoikilosis."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "We report five members of a family with dacryocystitis associated with osteopoikilosis. The inheritance is autosomal dominant."
        explanation: The original syndromic report establishing co-occurrence of dacryocystitis with osteopoikilosis in a single family with autosomal dominant inheritance.
phenotypes:
  - name: Dacryocystitis
    category: Ophthalmological
    frequency: OBLIGATE
    diagnostic: true
    description: >
      Chronic inflammation of the lacrimal sac due to nasolacrimal duct or
      lacrimal canal stenosis. Confirmed in the original family by lacrimal
      lavage and dacryocystography.
    sequelae:
      - target: Epiphora
    phenotype_term:
      preferred_term: Dacryocystitis
      term:
        id: HP:0000620
        label: Dacryocystitis
    evidence:
      - reference: PMID:8261652
        reference_title: "Dacryocystitis associated with osteopoikilosis."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "We report five members of a family with dacryocystitis associated with osteopoikilosis. The inheritance is autosomal dominant."
        explanation: All five affected members in the original pedigree had dacryocystitis.
  - name: Osteopoikilosis
    category: Skeletal
    frequency: OBLIGATE
    diagnostic: true
    description: >
      Multiple discrete spherical osteosclerotic bone islands (2-10mm diameter)
      visible on radiographic examination, distributed symmetrically in periarticular
      locations, particularly the epiphyses and metaphyses of long bones.
    sequelae:
      - target: Arthralgia
      - target: Joint Swelling
    phenotype_term:
      preferred_term: Osteopoikilosis
      term:
        id: HP:0010739
        label: Osteopoikilosis
    evidence:
      - reference: PMID:8261652
        reference_title: "Dacryocystitis associated with osteopoikilosis."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "We report five members of a family with dacryocystitis associated with osteopoikilosis. The inheritance is autosomal dominant."
        explanation: All five affected members in the original pedigree had osteopoikilosis demonstrated radiologically.
      - reference: PMID:17087626
        reference_title: "Deactivating germline mutations in LEMD3 cause osteopoikilosis and Buschke-Ollendorff syndrome, but not sporadic melorheostosis."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "OPK is an autosomal dominant, usually benign, skeletal dysplasia featuring multiple, small, especially metaphyseal, oval or round, dense trabecular foci distributed symmetrically throughout the skeleton."
        explanation: Characterizes the typical radiographic appearance of osteopoikilosis.
  - name: Lacrimal Duct Stenosis
    category: Ophthalmological
    frequency: FREQUENT
    diagnostic: false
    description: >
      Narrowing of the nasolacrimal duct or lacrimal canal, which is the
      prerequisite for the development of dacryocystitis in this syndrome.
    sequelae:
      - target: Dacryocystitis
        description: Lacrimal duct stenosis causes tear stasis and secondary infection of the lacrimal sac.
      - target: Epiphora
        description: Obstructed tear drainage leads to overflow tearing.
    phenotype_term:
      preferred_term: Lacrimal duct stenosis
      term:
        id: HP:0007678
        label: Lacrimal duct stenosis
    evidence:
      - reference: PMID:8261652
        reference_title: "Dacryocystitis associated with osteopoikilosis."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "We report five members of a family with dacryocystitis associated with osteopoikilosis. The inheritance is autosomal dominant."
        explanation: Dacryocystitis in the original family implies lacrimal duct stenosis as the underlying anatomical defect.
  - name: Increased Bone Mineral Density
    category: Skeletal
    frequency: OBLIGATE
    diagnostic: true
    description: >
      Osteosclerotic lesions characteristic of osteopoikilosis, representing
      focal areas of increased bone density visible on plain radiographs.
    phenotype_term:
      preferred_term: Increased bone mineral density
      term:
        id: HP:0011001
        label: Increased bone mineral density
    evidence:
      - reference: PMID:25352085
        reference_title: "Osteopoikilosis: report of a familial case and review of the literature."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Osteopoikilosis (OPK) is a benign, rare, asymptomatic osteosclerotic bone dysplasia which is inherited as an autosomal dominant trait."
        explanation: Osteosclerotic bone dysplasia directly implies increased bone mineral density at the lesion sites.
  - name: Epiphora
    category: Ophthalmological
    frequency: FREQUENT
    diagnostic: false
    description: >
      Overflow of tears due to impaired drainage through the stenosed
      nasolacrimal duct, a direct consequence of the lacrimal canal
      obstruction that characterizes this syndrome.
    phenotype_term:
      preferred_term: Epiphora
      term:
        id: HP:0009926
        label: Epiphora
    evidence:
      - reference: PMID:34986808
        reference_title: "Acquired nasolacrimal duct obstruction: clinical and histological findings of 275 cases."
        supports: PARTIAL
        evidence_source: HUMAN_CLINICAL
        snippet: "Epiphora with continuous purulent discharge was the most common clinical sign reported by 144 (52.4%) patients"
        explanation: Large clinical series confirms epiphora as the most common presenting symptom in acquired nasolacrimal duct obstruction with dacryocystitis.
  - name: Dupuytren Contracture
    category: Musculoskeletal
    frequency: OCCASIONAL
    diagnostic: false
    description: >
      Palmar fibromatosis leading to digital flexion contracture, reported in
      the same family with osteopoikilosis as part of a generalized
      fibroproliferative tendency.
    phenotype_term:
      preferred_term: Dupuytren contracture
      term:
        id: HP:0005679
        label: Dupuytren contracture
    evidence:
      - reference: PMID:14521305
        reference_title: "Disorders associated with osteopoikilosis: 5 different lesions in a family."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "We report a family in whom various members had osteopoikilosis with 5 different associated lesions. We suggest that osteopoikilosis is a bone manifestation of a generalized fibroproliferative or stenosing disease."
        explanation: Dupuytren contracture is among the fibroproliferative lesions reported in the Gunal family with osteopoikilosis.
  - name: Keloids
    category: Dermatological
    frequency: OCCASIONAL
    diagnostic: false
    description: >
      Tendency toward keloid scar formation, consistent with the
      fibroproliferative connective tissue phenotype observed in
      osteopoikilosis-associated conditions.
    phenotype_term:
      preferred_term: Keloids
      term:
        id: HP:0010562
        label: Keloids
    evidence:
      - reference: PMID:14521305
        reference_title: "Disorders associated with osteopoikilosis: 5 different lesions in a family."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "We report a family in whom various members had osteopoikilosis with 5 different associated lesions. We suggest that osteopoikilosis is a bone manifestation of a generalized fibroproliferative or stenosing disease."
        explanation: Keloid formation is among the fibroproliferative lesions reported in the Gunal family with osteopoikilosis.
  - name: Arthralgia
    category: Musculoskeletal
    frequency: OCCASIONAL
    diagnostic: false
    description: >
      Joint pain reported in 15-20% of osteopoikilosis patients,
      sometimes accompanied by joint swelling or effusion.
    phenotype_term:
      preferred_term: Arthralgia
      term:
        id: HP:0002829
        label: Arthralgia
    evidence:
      - reference: PMID:25352085
        reference_title: "Osteopoikilosis: report of a familial case and review of the literature."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Although it is usually asymptomatic, effusion and joint pain can be found in 15-20 % of patients."
        explanation: Documents that arthralgia occurs in a minority of osteopoikilosis patients.
  - name: Joint Swelling
    category: Musculoskeletal
    frequency: OCCASIONAL
    diagnostic: false
    description: >
      Joint swelling or effusion occasionally reported in osteopoikilosis
      patients, of unclear pathogenic significance.
    phenotype_term:
      preferred_term: Joint swelling
      term:
        id: HP:0001386
        label: Joint swelling
    evidence:
      - reference: PMID:25352085
        reference_title: "Osteopoikilosis: report of a familial case and review of the literature."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Although it is usually asymptomatic, effusion and joint pain can be found in 15-20 % of patients."
        explanation: Documents that joint effusion/swelling occurs in a minority of osteopoikilosis patients.
  - name: Digital Flexor Tenosynovitis
    category: Musculoskeletal
    frequency: VERY_RARE
    diagnostic: false
    description: >
      Stenosing tenosynovitis (trigger finger) reported in the Gunal family
      as part of the fibroproliferative spectrum of osteopoikilosis.
    phenotype_term:
      preferred_term: Digital flexor tenosynovitis
      term:
        id: HP:0012276
        label: Digital flexor tenosynovitis
    evidence:
      - reference: PMID:14521305
        reference_title: "Disorders associated with osteopoikilosis: 5 different lesions in a family."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "We report a family in whom various members had osteopoikilosis with 5 different associated lesions. We suggest that osteopoikilosis is a bone manifestation of a generalized fibroproliferative or stenosing disease."
        explanation: Trigger finger (stenosing digital flexor tenosynovitis) is among the lesions reported in the Gunal osteopoikilosis family.
genetic:
  - name: LEMD3
    association: Causative (inferred)
    notes: >
      Heterozygous loss-of-function mutations (truncating, frameshift, nonsense,
      whole-gene deletion) in LEMD3 (MAN1) cause osteopoikilosis. LEMD3 is not yet
      directly confirmed in the dacryocystitis-osteopoikilosis syndrome pedigree,
      but is the established genetic cause of isolated osteopoikilosis and
      Buschke-Ollendorff syndrome. Direct molecular genetic testing of the Gunal
      family has not been reported.
    evidence:
      - reference: PMID:15489854
        reference_title: "Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis."
        supports: PARTIAL
        evidence_source: HUMAN_CLINICAL
        snippet: "All the affected individuals that we investigated were heterozygous with respect to a loss-of-function mutation in LEMD3 (also called MAN1), which encodes an inner nuclear membrane protein."
        explanation: Identifies LEMD3 as the causative gene for osteopoikilosis in multiple families; LEMD3 is inferred (not directly tested) as the causative gene in the dacryocystitis-osteopoikilosis pedigree.
      - reference: PMID:17087626
        reference_title: "Deactivating germline mutations in LEMD3 cause osteopoikilosis and Buschke-Ollendorff syndrome, but not sporadic melorheostosis."
        supports: PARTIAL
        evidence_source: HUMAN_CLINICAL
        snippet: "We confirm that OPK and BOS individuals, including those with MEL-like lesions, have heterozygous, deactivating, germline LEMD3 mutations."
        explanation: Confirms deactivating LEMD3 mutations in additional OPK/BOS families; these families did not have the combined dacryocystitis phenotype, so this supports the inference but is not direct evidence for the combined syndrome.
diagnosis:
- name: Clinical, Radiographic, and Molecular Diagnosis
  description: >-
    Dacryocystitis-osteopoikilosis syndrome is diagnosed from the combination
    of recurrent dacryocystitis and the characteristic radiographic
    osteopoikilosis (symmetric small sclerotic foci in the epiphyses and
    metaphyses), inherited in an autosomal dominant manner, and is confirmed
    by identification of a heterozygous loss-of-function LEMD3 variant on
    molecular genetic testing. Lacrimal lavage or dacryocystography confirms
    nasolacrimal duct stenosis in patients with dacryocystitis. Note that LEMD3
    molecular testing has not been reported in the original dacryocystitis-
    osteopoikilosis pedigree; confirmation in affected families is an unmet need.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: MAXO:0000533
      label: molecular genetic testing
  evidence:
  - reference: PMID:8261652
    reference_title: "Dacryocystitis associated with osteopoikilosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report five members of a family with dacryocystitis associated with osteopoikilosis. The inheritance is autosomal dominant."
    explanation: >-
      Establishes the clinical association and autosomal dominant inheritance that define the syndrome.
  - reference: PMID:15489854
    reference_title: "Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All the affected individuals that we investigated were heterozygous with respect to a loss-of-function mutation in LEMD3 (also called MAN1), which encodes an inner nuclear membrane protein."
    explanation: >-
      Supports heterozygous loss-of-function LEMD3 molecular testing for confirmation of osteopoikilosis.
- name: Radiographic Diagnosis and Differential
  description: >-
    Plain radiographs are the primary modality for diagnosing osteopoikilosis,
    revealing the characteristic multiple, small, well-defined, symmetric
    periarticular sclerotic foci. A clinically important pitfall is confusion
    with osteoblastic bone metastases; bone scintigraphy is normal in OPK
    (unlike metastatic disease) and is the key discriminating investigation.
    Diagnosis is often incidental. When multiple symmetric sclerotic foci are
    identified, OPK should be included in the differential before alarming the
    patient with a cancer diagnosis.
  diagnosis_term:
    preferred_term: radiograph imaging procedure
    term:
      id: MAXO:0000595
      label: radiograph imaging procedure
  evidence:
  - reference: PMID:25352085
    reference_title: "Osteopoikilosis: report of a familial case and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "OPK must be in differential diagnosis when multiple, small, well-defined, symmetric bone lesions are identified on plain radiograph to avoid alarming the patient with more serious disease and misdiagnosis."
    explanation: >-
      Establishes plain radiograph as the primary diagnostic modality and highlights
      the clinically important differential diagnosis from osteoblastic metastases.
  - reference: PMID:25352085
    reference_title: "Osteopoikilosis: report of a familial case and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bone scintigraphy is normal and useful for differential diagnosis."
    explanation: >-
      Normal bone scintigraphy in OPK distinguishes it from metastatic bone disease,
      where scintigraphic uptake would be expected.
treatments:
  - name: Dacryocystorhinostomy
    description: >
      Surgical procedure to create a new drainage pathway from the lacrimal sac
      directly into the nasal cavity, bypassing the obstructed nasolacrimal duct.
      May be necessary in cases of chronic or recurrent dacryocystitis that do
      not respond to conservative management.
    treatment_term:
      preferred_term: dacryocystorhinostomy
      term:
        id: MAXO:0025005
        label: surgical procedure on nasolacrimal duct
  - name: Antibiotic Therapy
    description: >
      Antibiotics prescribed to manage acute bacterial infections associated with
      dacryocystitis episodes. Typically includes topical and systemic antibiotics.
    treatment_term:
      preferred_term: antibiotic pharmacotherapy
  - name: Observation and Reassurance for Osteopoikilosis
    description: >
      Osteopoikilosis itself is typically benign and asymptomatic, requiring no
      specific treatment in most cases. Affected individuals should be reassured
      of the non-progressive and non-malignant nature of the bone lesions.
      Clinical monitoring without intervention is appropriate for asymptomatic cases.
    treatment_term:
      preferred_term: supportive care
      term:
        id: MAXO:0000950
        label: supportive care
    evidence:
      - reference: PMID:25352085
        reference_title: "Osteopoikilosis: report of a familial case and review of the literature."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Osteopoikilosis (OPK) is a benign, rare, asymptomatic osteosclerotic bone dysplasia which is inherited as an autosomal dominant trait."
        explanation: Confirms osteopoikilosis is typically benign and asymptomatic, supporting a management approach of observation and reassurance rather than active intervention.
  - name: Analgesic Therapy for Arthralgia
    description: >
      For the minority of patients who develop joint pain (arthralgia) or joint
      effusion associated with periarticular osteosclerotic lesions, symptomatic
      management with analgesics or anti-inflammatory agents is appropriate.
      No disease-specific treatment is required for osteopoikilosis-associated
      arthralgia.
    treatment_term:
      preferred_term: pharmacotherapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy
    evidence:
      - reference: PMID:25352085
        reference_title: "Osteopoikilosis: report of a familial case and review of the literature."
        supports: PARTIAL
        evidence_source: HUMAN_CLINICAL
        snippet: "Although it is usually asymptomatic, effusion and joint pain can be found in 15-20 % of patients."
        explanation: Documents that a minority of osteopoikilosis patients experience joint symptoms warranting symptomatic pain management; specific analgesic regimens are not detailed in this report.
notes: >
  Dacryocystitis-osteopoikilosis syndrome (also known as Gunal-Seber-Basaran syndrome,
  OMIM:166705) is an exceedingly rare autosomal dominant disorder described in a single
  Turkish family of five affected individuals. The syndrome combines chronic dacryocystitis
  (due to lacrimal canal stenosis) with osteopoikilosis (discrete spherical osteosclerotic
  bone lesions). A follow-up study of the same family (Gunal & Kiter, 2003) identified
  5 different associated lesions in various family members, supporting the hypothesis that
  osteopoikilosis is the bone manifestation of a generalized fibroproliferative or stenosing
  connective tissue disorder. While LEMD3 mutations are established as causal for
  osteopoikilosis and Buschke-Ollendorff syndrome, direct molecular confirmation in this
  pedigree has not been reported. Osteopoikilosis itself is typically benign and
  asymptomatic, requiring no treatment; management focuses on dacryocystitis symptoms
  and any fibroproliferative complications.

📚

References & Deep Research

Deep Research

1

Falcon ▸

Disease Pathophysiology Research Template

Edison Scientific Literature 34 citations 2026-03-07T05:23:51.585167

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

Disease Name: Dacryocystitis-Osteopoikilosis Syndrome
MONDO ID: (if available)
Category: Mendelian

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Dacryocystitis-Osteopoikilosis Syndrome. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

What are the primary pathophysiological mechanisms?
What molecular pathways are dysregulated?
What cellular processes are affected?

2. Key Molecular Players

Genes/Proteins: Which genes are causally involved or implicated?
Chemical Entities: What metabolites, drugs, or small molecules are relevant?
Cell Types: Which cell types are primarily affected?
Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

What biological processes (GO terms) are disrupted?
Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

Where in the cell do key processes occur?
Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

What is the sequence of events from initial trigger to clinical manifestation?
Are there distinct stages or phases?

6. Phenotypic Manifestations

What are the key clinical phenotypes?
How do they relate to the underlying mechanisms?

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic claims
Prioritize recent reviews and landmark papers
Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Pathophysiology Research Report: Dacryocystitis–Osteopoikilosis Syndrome (Günal–Seber–Başaran syndrome)

0. Disease identity and scope

Disease: Dacryocystitis–osteopoikilosis syndrome (also referred to as Günal–Seber–Başaran syndrome). The disease is represented in MONDO as MONDO_0008158 (“dacryocystitis-osteopoikilosis syndrome”) and in Orphanet as Orphanet_1562 (“Dacryocystitis – osteopoikilosis”). (OpenTargets Search: Dacryocystitis-osteopoikilosis syndrome,Osteopoikilosis,Buschke-Ollendorff syndrome)

Clinical definition (core): Familial osteopoikilosis (multiple periarticular sclerotic foci) plus chronic dacryocystitis, thought to arise from lacrimal drainage stenosis. The original description is a multigenerational pedigree with five affected family members in which chronic dacryocystitis was confirmed by lacrimal lavage and dacryocystography alongside radiographic osteopoikilosis. (gunal1993dacryocystitisassociatedwith pages 1-3)

Interpretation for pathophysiology: Direct mechanistic studies in “dacryocystitis–osteopoikilosis syndrome” per se are sparse; therefore, current understanding largely derives from (i) the original pedigree-based description of the combined phenotype and proposed local mechanism for dacryocystitis, and (ii) robust genetic/mechanistic work defining the molecular basis of osteopoikilosis/Buschke–Ollendorff syndrome (BOS) due to LEMD3/MAN1 loss-of-function and dysregulated TGF-β/BMP–SMAD signaling. (gunal1993dacryocystitisassociatedwith pages 1-3, hellemans2004lossoffunctionmutationsin pages 3-4)

Condition/Entity	Citation	Publication Date	Key Findings	Mechanistic/Pathway Statements	Notes on Dacryocystitis/Lacrimal Stenosis	URL/DOI
Dacryocystitis-Osteopoikilosis Syndrome	Gunal et al. (1993) (gunal1993dacryocystitisassociatedwith pages 1-3, gunal1993dacryocystitisassociatedwith pages 3-3)	Oct 1993	Describes 5 family members with coexisting dacryocystitis and osteopoikilosis; suggests syndromic nature.	Proposes "stenosis of the lacrimal sac or canal" due to sclerotic/stenosing connective tissue disorder.	"As far as we know, dacryocystitis in patients with osteopoikilosis has not been recorded previously... The essential prerequisite for dacryocystitis is the stenosis of the lacrimal sac or canal."	10.1111/j.1399-0004.1993.tb03882.x
Osteopoikilosis / BOS / Melorheostosis	Hellemans et al. (2004) (hellemans2004lossoffunctionmutationsin pages 3-4, hellemans2004lossoffunctionmutationsin pages 1-2)	Oct 2004	Identifies LEMD3 loss-of-function mutations as causal for osteopoikilosis, BOS, and melorheostosis.	LEMD3 encodes MAN1 which "interacts with BMP and activin-TGF-beta receptor-activated Smads and antagonizes both signaling pathways."	No specific mention of dacryocystitis in this mechanistic paper.	10.1038/ng1453
Osteopoikilosis / BOS	Mumm et al. (2007) (mumm2007deactivatinggermlinemutations pages 1-2)	Feb 2007	Confirms LEMD3 LOF mutations in OPK/BOS; not found in sporadic melorheostosis.	Notes LEMD3 (MAN1) "antagonizes TGF-beta and BMP signaling" but offers no new mechanistic data in this excerpt.	No specific mention of dacryocystitis.	10.1359/jbmr.061102
Osteopoikilosis / BOS	Couto et al. (2007) (couto2007anovellemd3 pages 1-3, couto2007anovellemd3 pages 4-4)	Jul 2007	Reports novel LEMD3 mutation (c.2032C>T) co-segregating with OPK.	MAN1 "binds Smad2 and Smad3 and antagonizes transforming growth factor-B signalling."	No specific mention of dacryocystitis.	10.1007/s00223-007-9043-z
Buschke-Ollendorff Syndrome	Pope et al. (2016) (pope2016buschke–ollendorffsyndromea pages 1-2)	Apr 2016	Systematic review of BOS (594 papers screened); estimates incidence 1:20,000.	States "exact mechanism by which LEMD3 causes lesions is not yet understood" despite known LEMD3 link.	No mention of dacryocystitis or nasolacrimal stenosis in this review.	10.1111/bjd.14366
Osteopoikilosis (with complications)	Mortier & Docquier (2014) (mortier2014traumaticfracturein pages 2-3, mortier2014traumaticfracturein pages 1-2)	Jan 2014	Case report of fracture in OPK patient; summarizes known associations.	Mentions LEMD3 function in BMP/TGF-beta signaling via SMAD interaction.	Lists "dacryocystitis" among reported associations but provides no specific case details or mechanism.	10.1155/2014/520651
Osteopoikilosis (with De Quervain's)	Kaparov et al. (2011) (kaparov2011dequervain’ssyndrome pages 4-4)	Jun 2011	Links OPK to stenosing tenosynovitis (De Quervain's); discusses fibroproliferation.	Suggests "proliferation of metabolically active fibroblasts is involved in the pathogenesis" of associated lesions.	"The associated lesions of OPK show similar patterns: stenosing lesions... stenosis of the contents of the lacrimal sac" is a prerequisite for dacryocystitis.	10.1007/s00296-009-1239-2
BOS (General)	van Steensel et al. (2008) (steensel2008buschkeollendorfsyndromereport pages 1-2)	Jan 2008	Case report and molecular overview of BOS/OPK; confirms LEMD3 LOF.	LEMD3 "antagonizes both pathways" (BMP/TGF-beta) by inhibiting Smad6/7/Id2/Id3 upregulation.	No specific mention of dacryocystitis.	10.2174/1874372200802010005

Table: This table summarizes primary literature characterizing the clinical entity (Gunal-Seber-Basaran syndrome), the established molecular cause (LEMD3 loss-of-function), and proposed mechanisms linking osteosclerosis to soft tissue stenosis.

1. Core pathophysiology (molecular → cellular → tissue)

1.1 Primary pathophysiological mechanisms

Primary molecular defect (best-supported across the spectrum): Osteopoikilosis (and the closely related BOS phenotype) is caused by heterozygous loss-of-function mutations in LEMD3 (also known as MAN1), which encodes an inner nuclear membrane protein whose C-terminal region binds receptor-activated SMADs and antagonizes TGF-β and BMP signaling. (hellemans2004lossoffunctionmutationsin pages 3-4, hellemans2004lossoffunctionmutationsin pages 1-2, mortier2014traumaticfracturein pages 2-3)

Dominant inheritance model: Human genetic evidence supports monoallelic (autosomal dominant) inheritance for osteopoikilosis and BOS, consistent with haploinsufficiency or functional truncation of MAN1/LEMD3. (hellemans2004lossoffunctionmutationsin pages 3-4, OpenTargets Search: Dacryocystitis-osteopoikilosis syndrome,Osteopoikilosis,Buschke-Ollendorff syndrome)

Tissue-level consequences: Osteopoikilosis lesions represent focal osteosclerosis (radiographically small, discrete sclerotic foci) and have been described as reflecting a defective endochondral bone maturation process with characteristic radiographic distribution. (mortier2014traumaticfracturein pages 1-2)

How dacryocystitis fits (hypothesis from primary syndrome report): The 1993 syndrome report proposed that the necessary prerequisite for dacryocystitis is stenosis of the lacrimal sac/canal, and suggested that such stenosis may arise in the context of osteopoikilosis-associated stenosing connective tissue abnormalities. (gunal1993dacryocystitisassociatedwith pages 3-3)

1.2 Dysregulated pathways

TGF-β/BMP–SMAD signaling antagonism by LEMD3/MAN1: In the landmark genetic study, the LEMD3 C-terminus was shown to interact with SMAD MH2 domains (e.g., Smad1 for BMP and Smad2 for TGF-β), and LEMD3 overexpression suppressed BMP- and TGF-β–responsive reporter and transcriptional readouts, supporting LEMD3 as a negative regulator (antagonist) of both BMP and TGF-β/SMAD signaling. (hellemans2004lossoffunctionmutationsin pages 3-4, hellemans2004lossoffunctionmutationsin pages 1-2)

Downstream functional effects relevant to bone: A 2024 authoritative review of bone biology emphasizes that BMPs promote osteogenesis, while TGF-β functions are stage-dependent in osteoblast/chondrocyte lineage progression and skeletal homeostasis; regulatory machinery includes cytoplasmic and nuclear control of SMAD signaling. This contextualizes why disinhibition of these pathways (via reduced LEMD3 antagonism) plausibly perturbs bone patterning/remodeling. (wu2024therolesand)

Note: The Wu et al. review was retrieved but not processed into a citable evidence snippet ID by the evidence tool in the current run; therefore, it is not cited further here to avoid unsupported claims.

1.3 Cellular processes affected

From the mechanistic and clinical literature, the most defensible disrupted processes include: - SMAD signal transduction regulation (loss of antagonism → increased signaling output). (hellemans2004lossoffunctionmutationsin pages 3-4) - Bone formation / endochondral ossification maturation abnormalities (osteopoikilosis described as defective endochondral maturation). (mortier2014traumaticfracturein pages 1-2) - Fibroproliferative/stenosing lesion tendency as a putative shared process across osteopoikilosis-associated “stenosing lesions” (hypothesis). (kaparov2011dequervain’ssyndrome pages 4-4, gunal1993dacryocystitisassociatedwith pages 3-3)

2. Key molecular players

2.1 Genes/proteins

Causal gene (core): - LEMD3 (HGNC symbol: LEMD3; protein: MAN1) — inner nuclear membrane protein, binds receptor-regulated SMADs, antagonizes TGF-β/BMP signaling. (hellemans2004lossoffunctionmutationsin pages 3-4, mortier2014traumaticfracturein pages 2-3)

Variant spectrum (examples): - Whole-gene deletion and multiple truncating variants (frameshift, nonsense, splice) were reported in affected families, consistent with loss-of-function and haploinsufficiency/truncation removing the SMAD-interacting C-terminus. (hellemans2004lossoffunctionmutationsin pages 3-4, hellemans2004lossoffunctionmutationsin pages 1-2) - Additional families show segregating nonsense variants and the absence of the variant in large control sets (e.g., 342 controls), supporting pathogenicity. (couto2007anovellemd3 pages 1-3)

Evidence gap for the specific syndrome label: Open Targets currently lists no curated gene target for “dacryocystitis–osteopoikilosis syndrome” even though it links LEMD3 to osteopoikilosis (and related entries), indicating that the lacrimal phenotype is not yet integrated into some gene–disease curation pipelines. (OpenTargets Search: Dacryocystitis-osteopoikilosis syndrome,Osteopoikilosis,Buschke-Ollendorff syndrome)

2.2 Chemical entities (metabolites/drugs/small molecules)

No disease-specific metabolite or drug mechanism is established for the syndrome in the retrieved evidence. Clinical care is therefore symptom- and complication-directed (e.g., pain control in symptomatic osteopoikilosis; standard ophthalmologic management for nasolacrimal obstruction/infection).

2.3 Cell types primarily affected (inferred from mechanism)

Osteoblast lineage / bone-forming mesenchymal cells — implicated by bone sclerosis phenotype and BMP/TGF-β roles in osteogenesis. (hellemans2004lossoffunctionmutationsin pages 3-4, mortier2014traumaticfracturein pages 1-2)
Fibroblasts — implicated both by (i) enhanced TGF-β signaling in fibroblast context reported in the LEMD3 LOF study and (ii) hypothesis of fibroblast-driven fibroproliferation/stenosis in associated lesions. (hellemans2004lossoffunctionmutationsin pages 3-4, kaparov2011dequervain’ssyndrome pages 4-4)

2.4 Anatomical locations

Skeleton (multiple bones; periarticular regions): radiographic lesions in phalanges, carpus, metacarpals, radius/ulna reported in the syndrome pedigree. (gunal1993dacryocystitisassociatedwith pages 1-3)
Lacrimal drainage system: lacrimal sac/canal stenosis proposed as prerequisite for chronic dacryocystitis in the syndrome. (gunal1993dacryocystitisassociatedwith pages 3-3)

3. Biological processes disrupted (GO-oriented)

Below are ontology-ready candidate processes consistent with the cited evidence (mechanistic and clinical), suitable for GO annotation in a knowledge base:

Regulation of BMP signaling pathway (LEMD3 antagonizes BMP-SMAD signaling). (hellemans2004lossoffunctionmutationsin pages 3-4)
Regulation of TGF-β receptor signaling pathway (LEMD3 antagonizes TGF-β/activin SMAD signaling). (hellemans2004lossoffunctionmutationsin pages 3-4, couto2007anovellemd3 pages 4-4)
SMAD protein signal transduction / negative regulation of SMAD signaling (direct SMAD binding and pathway antagonism). (hellemans2004lossoffunctionmutationsin pages 3-4)
Endochondral ossification / bone maturation (osteopoikilosis described as defective endochondral maturation). (mortier2014traumaticfracturein pages 1-2)
Fibroblast proliferation / extracellular matrix organization / tissue stenosis (hypothesis) to connect “stenosing lesions” (e.g., lacrimal stenosis; other fibroproliferative lesions) with shared pathophysiology. (kaparov2011dequervain’ssyndrome pages 4-4, gunal1993dacryocystitisassociatedwith pages 3-3)

4. Cellular components (GO-CC oriented)

Inner nuclear membrane (LEMD3/MAN1 localization). (hellemans2004lossoffunctionmutationsin pages 3-4, couto2007anovellemd3 pages 4-4)
Nuclear envelope (broader compartment consistent with inner nuclear membrane proteins). (hellemans2004lossoffunctionmutationsin pages 3-4)
SMAD protein complexes / nucleus (functional interaction site for SMAD-mediated transcriptional regulation; supported by LEMD3–SMAD interaction and effects on transcriptional reporters). (hellemans2004lossoffunctionmutationsin pages 3-4)

5. Disease progression model (sequence of events)

5.1 Initiation and early molecular events

Germline heterozygous LEMD3 loss-of-function → reduced functional MAN1 at the inner nuclear membrane. (hellemans2004lossoffunctionmutationsin pages 3-4, OpenTargets Search: Dacryocystitis-osteopoikilosis syndrome,Osteopoikilosis,Buschke-Ollendorff syndrome)
Reduced antagonism of receptor-activated SMADs → increased effective output of BMP and/or TGF-β signaling programs in responsive cells. (hellemans2004lossoffunctionmutationsin pages 3-4)

5.2 Tissue remodeling and lesion development

In bone, altered morphogen signaling plausibly skews osteoblast/chondrocyte programs and remodeling, producing focal sclerotic bone islands typical of osteopoikilosis; clinically often incidental but can be associated with pain/effusions. (mortier2014traumaticfracturein pages 1-2)
In soft tissues, a subset of individuals may manifest stenosing/fibroproliferative changes (hypothesis) in anatomic conduits, including the nasolacrimal system. (kaparov2011dequervain’ssyndrome pages 4-4, gunal1993dacryocystitisassociatedwith pages 3-3)

5.3 Clinical manifestation

Nasolacrimal obstruction/stenosis predisposes to stasis and infection/inflammation, manifesting as chronic dacryocystitis. The syndrome report explicitly frames lacrimal stenosis as the prerequisite event. (gunal1993dacryocystitisassociatedwith pages 3-3)

6. Phenotypic manifestations and mechanistic links

6.1 Key phenotypes

Osteopoikilosis: multiple small, symmetric periarticular sclerotic lesions; may be asymptomatic and incidental. (mortier2014traumaticfracturein pages 1-2)
Chronic dacryocystitis: confirmed in the original family by lacrimal lavage/dacryocystography. (gunal1993dacryocystitisassociatedwith pages 1-3)

6.2 Mechanistic link between bone and lacrimal disease (strength of evidence)

Strong evidence for bone/connective tissue molecular mechanism: LEMD3 LOF → disinhibited BMP/TGF-β–SMAD signaling (primary mechanistic evidence). (hellemans2004lossoffunctionmutationsin pages 3-4)
Moderate evidence for lacrimal mechanism (clinical/hypothesis): lacrimal stenosis as prerequisite for dacryocystitis; “stenosing lesions” concept across osteopoikilosis-associated conditions (hypothesis). (gunal1993dacryocystitisassociatedwith pages 3-3, kaparov2011dequervain’ssyndrome pages 4-4)
Gap: No retrieved study directly assays LEMD3/TGF-β/BMP-SMAD signaling in lacrimal sac epithelium/stroma in affected patients; therefore, the lacrimal connection remains primarily anatomical/clinical and hypothesis-driven based on stenosis biology.

7. Recent developments (priority 2023–2024)

7.1 2024 clinical updates (real-world implementations)

Recent case literature continues to treat osteopoikilosis primarily as a benign radiographic diagnosis where the main clinical “implementation” is avoiding misdiagnosis (e.g., metastatic disease) and managing symptoms conservatively; these papers often reiterate LEMD3 as the likely causal gene but typically do not add new mechanistic tissue-level work. (alghamdi2024ararecase pages 4-5)

7.2 2023–2024 knowledge gaps specific to the syndrome

No 2023–2024 publications were retrieved here that (i) re-define the dacryocystitis–osteopoikilosis syndrome at the molecular level, (ii) provide lacrimal tissue functional work, or (iii) establish genotype–phenotype correlations explaining why only a minority develop dacryocystitis.

8. Statistics and data

Syndrome case count (primary pedigree): 5 affected members with chronic dacryocystitis and osteopoikilosis in the original report. (gunal1993dacryocystitisassociatedwith pages 1-3)
BOS epidemiology (related disorder; contextual): In a systematic review/case series of BOS, estimated incidence 1 in 20,000, and among compiled cases, family history 92%; phenotypic distribution included skin-only 24%, bone-only 20%, and both 54%. (pope2016buschke–ollendorffsyndromea pages 1-2)

Note: These BOS statistics provide context for the LEMD3-related spectrum; they should not be directly interpreted as prevalence of dacryocystitis–osteopoikilosis syndrome.

9. Expert opinions and authoritative interpretations (from the cited literature)

The original syndrome authors highlight a mechanistic prerequisite: “The essential prerequisite for dacryocystitis is the stenosis of the lacrimal sac or canal”, framing the lacrimal phenotype as obstruction-driven rather than primary infection. (gunal1993dacryocystitisassociatedwith pages 3-3)
A rheumatology review case discussion suggests a unifying theme that osteopoikilosis-associated lesions show “stenosing lesions” patterns and links dacryocystitis risk to lacrimal sac stenosis, proposing shared fibroproliferative mechanisms (hypothesis). (kaparov2011dequervain’ssyndrome pages 4-4)
The landmark genetics study provides the mechanistic anchor: LEMD3/MAN1 functions as an inner nuclear membrane antagonist of BMP and TGF-β/SMAD signaling and LOF mutations underlie osteopoikilosis/BOS. (hellemans2004lossoffunctionmutationsin pages 3-4)

10. Knowledge-base ready annotation blocks

10.1 Pathophysiology description (concise)

Dacryocystitis–osteopoikilosis syndrome is a dominantly inherited phenotype combining osteopoikilosis with chronic dacryocystitis. Osteopoikilosis is best explained by monoallelic loss-of-function in LEMD3 (MAN1), an inner nuclear membrane SMAD-binding protein that antagonizes BMP and TGF-β/activin signaling; reduced MAN1 activity increases SMAD signaling output and perturbs bone maturation/remodeling, producing focal osteosclerotic lesions. The dacryocystitis component is proposed to arise secondarily from stenosis of the lacrimal drainage system, potentially reflecting a shared propensity for stenosing/fibroproliferative connective tissue lesions in the osteopoikilosis spectrum, but direct lacrimal tissue mechanistic validation is lacking. (hellemans2004lossoffunctionmutationsin pages 3-4, mortier2014traumaticfracturein pages 1-2, gunal1993dacryocystitisassociatedwith pages 3-3, kaparov2011dequervain’ssyndrome pages 4-4)

10.2 Gene/protein annotations

HGNC: LEMD3 (MAN1)
Molecular function / pathway (annotation-ready): negative regulation of BMP signaling; negative regulation of TGF-β receptor signaling; SMAD binding. (hellemans2004lossoffunctionmutationsin pages 3-4)

10.3 Phenotype associations (HPO-oriented; candidate terms)

Osteopoikilosis / osteosclerosis (radiographic sclerotic bone lesions). (mortier2014traumaticfracturein pages 1-2, gunal1993dacryocystitisassociatedwith pages 1-3)
Dacryocystitis (chronic). (gunal1993dacryocystitisassociatedwith pages 1-3)
Nasolacrimal duct/lacrimal sac stenosis or obstruction (as prerequisite mechanism; may map to lacrimal drainage obstruction terms). (gunal1993dacryocystitisassociatedwith pages 3-3)

10.4 Cell type involvement (CL-oriented; candidates)

Osteoblast / osteoprogenitor cell (bone sclerosis phenotype; BMP/TGF-β relevance). (hellemans2004lossoffunctionmutationsin pages 3-4)
Fibroblast (enhanced TGF-β signaling in fibroblasts reported; fibroproliferation hypothesis). (hellemans2004lossoffunctionmutationsin pages 3-4, kaparov2011dequervain’ssyndrome pages 4-4)

10.5 Anatomical locations (UBERON-oriented; candidates)

Bone (multiple; periarticular regions) (gunal1993dacryocystitisassociatedwith pages 1-3)
Lacrimal sac / nasolacrimal duct (gunal1993dacryocystitisassociatedwith pages 3-3)

10.6 Chemical entities (ChEBI-oriented)

No syndrome-specific small-molecule entities are established in the retrieved mechanistic literature.

11. Evidence items with PMIDs (where available in retrieved evidence)

LEMD3 genetic association evidence includes literature identifiers such as PMID: 15489854 referenced by Open Targets for osteopoikilosis (corresponding to the landmark 2004 Nature Genetics paper), and additional PMIDs listed in the same Open Targets evidence bundle. (OpenTargets Search: Dacryocystitis-osteopoikilosis syndrome,Osteopoikilosis,Buschke-Ollendorff syndrome)

Note: The full PMID list for each paper was not uniformly extracted into the evidence snippets in this run; for operational knowledge-base ingestion, cross-referencing each DOI to PubMed will yield canonical PMIDs.

12. Limitations and future directions

Direct molecular confirmation for the dacryocystitis-osteopoikilosis syndromic label (i.e., sequencing LEMD3 in confirmed lacrimal+OPK pedigrees and functional assays in lacrimal tissues) remains an unmet need in the retrieved corpus. (OpenTargets Search: Dacryocystitis-osteopoikilosis syndrome,Osteopoikilosis,Buschke-Ollendorff syndrome, gunal1993dacryocystitisassociatedwith pages 1-3)
Mechanistic bridging studies are needed to test whether MAN1/LEMD3 loss alters fibrosis/stenosis programs in nasolacrimal tissues (e.g., fibroblast activation, ECM deposition), which is currently supported mainly by clinical reasoning and analogy to other stenosing lesions. (kaparov2011dequervain’ssyndrome pages 4-4, gunal1993dacryocystitisassociatedwith pages 3-3)

References

(OpenTargets Search: Dacryocystitis-osteopoikilosis syndrome,Osteopoikilosis,Buschke-Ollendorff syndrome): Open Targets Query (Dacryocystitis-osteopoikilosis syndrome,Osteopoikilosis,Buschke-Ollendorff syndrome, 3 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(gunal1993dacryocystitisassociatedwith pages 1-3): I. Günal, S. Seber, N. Basaran, S. Artan, K. Günal, and E. Gokturk. Dacryocystitis associated with osteopoikilosis. Clinical Genetics, 44:211-213, Oct 1993. URL: https://doi.org/10.1111/j.1399-0004.1993.tb03882.x, doi:10.1111/j.1399-0004.1993.tb03882.x. This article has 47 citations and is from a peer-reviewed journal.
(hellemans2004lossoffunctionmutationsin pages 3-4): Jan Hellemans, Olena Preobrazhenska, Andy Willaert, Philippe Debeer, Peter C M Verdonk, Teresa Costa, Katrien Janssens, Bjorn Menten, Nadine Van Roy, Stefan J T Vermeulen, Ravi Savarirayan, Wim Van Hul, Filip Vanhoenacker, Danny Huylebroeck, Anne De Paepe, Jean-Marie Naeyaert, Jo Vandesompele, Frank Speleman, Kristin Verschueren, Paul J Coucke, and Geert R Mortier. Loss-of-function mutations in lemd3 result in osteopoikilosis, buschke-ollendorff syndrome and melorheostosis. Nature Genetics, 36:1213-1218, Oct 2004. URL: https://doi.org/10.1038/ng1453, doi:10.1038/ng1453. This article has 567 citations and is from a highest quality peer-reviewed journal.
(gunal1993dacryocystitisassociatedwith pages 3-3): I. Günal, S. Seber, N. Basaran, S. Artan, K. Günal, and E. Gokturk. Dacryocystitis associated with osteopoikilosis. Clinical Genetics, 44:211-213, Oct 1993. URL: https://doi.org/10.1111/j.1399-0004.1993.tb03882.x, doi:10.1111/j.1399-0004.1993.tb03882.x. This article has 47 citations and is from a peer-reviewed journal.
(hellemans2004lossoffunctionmutationsin pages 1-2): Jan Hellemans, Olena Preobrazhenska, Andy Willaert, Philippe Debeer, Peter C M Verdonk, Teresa Costa, Katrien Janssens, Bjorn Menten, Nadine Van Roy, Stefan J T Vermeulen, Ravi Savarirayan, Wim Van Hul, Filip Vanhoenacker, Danny Huylebroeck, Anne De Paepe, Jean-Marie Naeyaert, Jo Vandesompele, Frank Speleman, Kristin Verschueren, Paul J Coucke, and Geert R Mortier. Loss-of-function mutations in lemd3 result in osteopoikilosis, buschke-ollendorff syndrome and melorheostosis. Nature Genetics, 36:1213-1218, Oct 2004. URL: https://doi.org/10.1038/ng1453, doi:10.1038/ng1453. This article has 567 citations and is from a highest quality peer-reviewed journal.
(mumm2007deactivatinggermlinemutations pages 1-2): Steven Mumm, Deborah Wenkert, Xiafang Zhang, William H McAlister, Richard J Mier, and Michael P Whyte. Deactivating germline mutations in lemd3 cause osteopoikilosis and buschke-ollendorff syndrome, but not sporadic melorheostosis. Journal of Bone and Mineral Research, 22:243-250, Feb 2007. URL: https://doi.org/10.1359/jbmr.061102, doi:10.1359/jbmr.061102. This article has 107 citations and is from a highest quality peer-reviewed journal.
(couto2007anovellemd3 pages 1-3): Ana R. Couto, Jacome Bruges-Armas, Chris A. Peach, Kay Chapman, Matthew A. Brown, B. Paul Wordsworth, and Yun Zhang. A novel lemd3 mutation common to patients with osteopoikilosis with and without melorheostosis. Calcified Tissue International, 81:81-84, Jul 2007. URL: https://doi.org/10.1007/s00223-007-9043-z, doi:10.1007/s00223-007-9043-z. This article has 59 citations and is from a peer-reviewed journal.
(couto2007anovellemd3 pages 4-4): Ana R. Couto, Jacome Bruges-Armas, Chris A. Peach, Kay Chapman, Matthew A. Brown, B. Paul Wordsworth, and Yun Zhang. A novel lemd3 mutation common to patients with osteopoikilosis with and without melorheostosis. Calcified Tissue International, 81:81-84, Jul 2007. URL: https://doi.org/10.1007/s00223-007-9043-z, doi:10.1007/s00223-007-9043-z. This article has 59 citations and is from a peer-reviewed journal.
(pope2016buschke–ollendorffsyndromea pages 1-2): V. Pope, L. Dupuis, P. Kannu, R. Mendoza-Londono, D. Sajic, J. So, G. Yoon, and I. Lara‐Corrales. Buschke–ollendorff syndrome: a novel case series and systematic review. British Journal of Dermatology, 174:723-729, Apr 2016. URL: https://doi.org/10.1111/bjd.14366, doi:10.1111/bjd.14366. This article has 52 citations and is from a highest quality peer-reviewed journal.
(mortier2014traumaticfracturein pages 2-3): Adeline Du Mortier and Pierre-Louis Docquier. Traumatic fracture in a patient with osteopoikilosis. Case Reports in Orthopedics, 2014:1-4, Jan 2014. URL: https://doi.org/10.1155/2014/520651, doi:10.1155/2014/520651. This article has 1 citations.
(mortier2014traumaticfracturein pages 1-2): Adeline Du Mortier and Pierre-Louis Docquier. Traumatic fracture in a patient with osteopoikilosis. Case Reports in Orthopedics, 2014:1-4, Jan 2014. URL: https://doi.org/10.1155/2014/520651, doi:10.1155/2014/520651. This article has 1 citations.
(kaparov2011dequervain’ssyndrome pages 4-4): Asylbek Kaparov, Murat Uludag, Hidayet Sari, and Ülkü Akarirmak. De quervain’s syndrome associated with osteopoikilosis: a case report and review of the literature. Rheumatology International, 31:809-813, Jun 2011. URL: https://doi.org/10.1007/s00296-009-1239-2, doi:10.1007/s00296-009-1239-2. This article has 11 citations and is from a peer-reviewed journal.
(steensel2008buschkeollendorfsyndromereport pages 1-2): Maurice A.M. van Steensel, Michel van Geel, Valerie L.R.M. Verstraeten, and G.P. H. Lucker. Buschke-ollendorf syndrome: report of a case and a brief molecular overview. The Open Dermatology Journal, 2:5-8, Jan 2008. URL: https://doi.org/10.2174/1874372200802010005, doi:10.2174/1874372200802010005. This article has 0 citations.
(alghamdi2024ararecase pages 4-5): Bandar A Alghamdi. A rare case of hereditary bone dysplasia: osteopoikilosis in a mother and her son. Cureus, Jun 2024. URL: https://doi.org/10.7759/cureus.61477, doi:10.7759/cureus.61477. This article has 2 citations.

Ask OpenScientist

OpenScientist Report

Inheritance

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Treatments

Source YAML

References & Deep Research

Deep Research

Disease Pathophysiology Research Template

Target Disease

Research Objectives

Required Information

1. Core Pathophysiology

2. Key Molecular Players

3. Biological Processes (for GO annotation)

4. Cellular Components

5. Disease Progression

6. Phenotypic Manifestations

Citation Requirements

Output Format

Pathophysiology Research Report: Dacryocystitis–Osteopoikilosis Syndrome (Günal–Seber–Başaran syndrome)

0. Disease identity and scope

1. Core pathophysiology (molecular → cellular → tissue)

1.1 Primary pathophysiological mechanisms

1.2 Dysregulated pathways

1.3 Cellular processes affected

2. Key molecular players

2.1 Genes/proteins

2.2 Chemical entities (metabolites/drugs/small molecules)

2.3 Cell types primarily affected (inferred from mechanism)

2.4 Anatomical locations

3. Biological processes disrupted (GO-oriented)

4. Cellular components (GO-CC oriented)

5. Disease progression model (sequence of events)

5.1 Initiation and early molecular events

5.2 Tissue remodeling and lesion development

5.3 Clinical manifestation

6. Phenotypic manifestations and mechanistic links

6.1 Key phenotypes

6.2 Mechanistic link between bone and lacrimal disease (strength of evidence)

7. Recent developments (priority 2023–2024)

7.1 2024 clinical updates (real-world implementations)

7.2 2023–2024 knowledge gaps specific to the syndrome

8. Statistics and data

9. Expert opinions and authoritative interpretations (from the cited literature)

10. Knowledge-base ready annotation blocks

10.1 Pathophysiology description (concise)

10.2 Gene/protein annotations

10.3 Phenotype associations (HPO-oriented; candidate terms)

10.4 Cell type involvement (CL-oriented; candidates)

10.5 Anatomical locations (UBERON-oriented; candidates)

10.6 Chemical entities (ChEBI-oriented)

11. Evidence items with PMIDs (where available in retrieved evidence)

12. Limitations and future directions